Caitong International Asset Management Co., LTD Inozyme Pharma, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 425 shares of INZY stock, worth $582. This represents 0.0% of its overall portfolio holdings.
Number of Shares
425
Previous 425
-0.0%
Holding current value
$582
Previous $1.18 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
103Shares Held
50.7MCall Options Held
2.6KPut Options Held
5.1K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$7.07 Million0.03% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$6.16 Million11.45% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$5.86 Million0.97% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.97MShares$5.44 Million1.97% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.86MShares$5.29 Million0.43% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $55M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...